Explore jobs
Find specific jobs
Explore careers
Explore professions
Best companies
Explore companies
Nurix history
Nurix company history timeline
Since joining Nurix in 2015, Gwenn has focused on establishing the company’s DNA encoded library technology platform for small molecule discovery in addition to leading the discovery organization.
Prior to 2015, Michael worked in a variety of roles at Eli Lilly and Company, ImClone Systems, Millennium Pharmaceuticals, Inhale Therapeutics, and IDEC Pharmaceuticals.
Janine Powers, Ph.D., has served as Head of Translational Medicine at Nurix since September 2018.
In June 2019, Nurix entered into a global strategic collaboration with Gilead to discover, develop, and commercialize a pipeline of innovative targeted protein degradation drugs for patients with cancer and other challenging diseases.
Lori A. Kunkel, M.D., has served as a member of our board of directors since July 2019.
In January 2020, Nurix entered into a global strategic collaboration with Sanofi to discover, develop, and commercialize a pipeline of innovative targeted protein degradation drugs for patients with challenging diseases.
Raf Lambrecht has served as Head of Regulatory Affairs at Nurix since April 2020.
Michael T. Lotze, M.D. has served as Chief Cellular Therapy Officer of Nurix since June 2020.
In January 2021, Nurix announced the expansion of its strategic collaboration with Sanofi, increasing the number of targets from three to a total of five.
Su Young Kim, M.D., Ph.D., has served as Nurix’s Vice President of Clinical Development since May 2021.
James Nelson has served as Vice President of Quality Assurance at Nurix since September 2021.
Paul M. Silva has served as a member of our board of directors since October 2021.
©2022 Nurix Therapeutics, Inc.
Rate how well Nurix lives up to its initial vision.
Nurix jobs
Do you work at Nurix?
Does Nurix communicate its history to new hires?
Nurix competitors
| Company name | Founded date | Revenue | Employee size | Job openings |
|---|---|---|---|---|
| Cognition Therapeutics | 2007 | $19.5M | 30 | - |
| Panacos Pharmaceuticals | - | - | 20 | - |
| Frequency Therapeutics | 2015 | $2.3M | 83 | - |
| eFFECTOR Therapeutics | 2012 | $42.0M | 24 | - |
| Kezar Life Sciences | 2015 | $7.0M | 20 | - |
| Tetralogic Pharmaceuticals | 2001 | - | 20 | - |
| Tensha Therapeutics | 2011 | $180,000 | 5 | - |
| Ribometrix | 2014 | $2.0M | 44 | - |
| Aquinox Pharmaceuticals | 2004 | - | 9 | - |
Nurix history FAQs
Zippia gives an in-depth look into the details of Nurix, including salaries, political affiliations, employee data, and more, in order to inform job seekers about Nurix. The employee data is based on information from people who have self-reported their past or current employments at Nurix. The data on this page is also based on data sources collected from public and open data sources on the Internet and other locations, as well as proprietary data we licensed from other companies. Sources of data may include, but are not limited to, the BLS, company filings, estimates based on those filings, H1B filings, and other public and private datasets. While we have made attempts to ensure that the information displayed are correct, Zippia is not responsible for any errors or omissions or for the results obtained from the use of this information. None of the information on this page has been provided or approved by Nurix. The data presented on this page does not represent the view of Nurix and its employees or that of Zippia.
Nurix may also be known as or be related to NURIX THERAPEUTICS, INC., Nurix, Nurix, Inc and Nurix, Inc.